** Brokerage Wells Fargo initiates coverage on medtech firm LeMaitre Vascular LMAT.O with an "equal weight" rating and a PT of $95
** Brokerage says LMAT could be poised for growth in 2025 if it pursues strategic mergers and acquisitions; adds that the company has $300 million available for deals that could bolster its device portfolio
** Wells Fargo observes LMAT may acquire companies that make surgical sealants, devices that block blood flow and clips for tying off blood vessels
** "We believe that the stock fully prices in an optimistic outlook for pricing and volume growth in 2025 and beyond" - brokerage
** Stock up about 55% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。